<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002557</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000063440</org_study_id>
    <secondary_id>SAFR-CT-MF-2</secondary_id>
    <secondary_id>NCI-F94-0015</secondary_id>
    <nct_id>NCT00002557</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy in Patients With Advanced or Recurrent Mycosis Fungoides</brief_title>
  <official_title>PROTOCOL FOR THE MANAGEMENT OF MYCOSIS FUNGOIDES AND THE SEZARY SYNDROME</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die. Combining more than one drug may kill more tumor cells.

      PURPOSE: Phase II trial to study the effectiveness of etoposide with or without doxorubicin
      and methotrexate in treating patients who have mycosis fungoides.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Assess the response rate in patients with Stage III/IV or recurrent mycosis
      fungoides or Sezary syndrome treated with oral etoposide, with the addition of doxorubicin,
      then methotrexate for poor responders. II. Assess changes in the hematologic and immunologic
      status of the tumor in these patients.

      OUTLINE: Patients are treated sequentially on Regimens A, B, and C depending on response. The
      following acronyms are used: CF Leucovorin calcium, NSC-3590 DOX Doxorubicin, NSC-123127 MTX
      Methotrexate, NSC-740 VP-16 Etoposide, NSC-141540 Regimen A: Single-Agent Chemotherapy.
      VP-16. Regimen B: 2-Drug Combination Chemotherapy. VP-16/DOX. Regimen C: 3-Drug Combination
      Chemotherapy. VP-16/DOX/MTX.

      PROJECTED ACCRUAL: Study duration will be at least 3 years with an anticipated accrual of 3
      patients/year.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 1993</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">3</enrollment>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHOP regimen</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Stage III/IV mycosis fungoides or Sezary syndrome Stage I/II
        cutaneous T-cell lymphoma in relapse following interferon therapy also eligible

        PATIENT CHARACTERISTICS: Age: Not specified

        PRIOR CONCURRENT THERAPY: Biologic therapy: Prior interferon alpha for Stage I/II disease
        allowed Chemotherapy: Prior isotretinoin for Stage I/II disease allowed Endocrine therapy:
        Prior topical steroids for Stage I/II disease allowed Radiotherapy: Prior ultraviolet
        therapy for Stage I/II disease allowed Prior x-ray therapy for Stage I/II disease allowed
        Surgery: Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolas Novitzky, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Cape Town</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Cape Town School of Medicine</name>
      <address>
        <city>Cape Town</city>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <verification_date>August 2000</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>July 16, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2004</study_first_posted>
  <last_update_submitted>December 17, 2013</last_update_submitted>
  <last_update_submitted_qc>December 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2013</last_update_posted>
  <keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Mycosis Fungoides</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

